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Chagas disease vector control is among the great-
est public health achievements ever. The impact of the 
Inter-Government Initiatives coordinated by the Pan 
American Health Organization/World Health Organi-
zation (PAHO/WHO) has been enormous, with large 
reductions of incidence, prevalence and disease burden 
(Schofield et al. 2006). Yet, when entomological sur-
veillance breaks down, native vectors re-invade and re-
infest human residences, leading to the re-emergence 
of transmission (Gürtler et al. 2007). In fact, and as 
with other zoonoses, eradication of Chagas disease is 
impossible: sporadic Trypanosoma cruzi transmission 
to humans will always occur, even in the presence of 
the best conceivable control program (Schofield et al. 
2006, Tarleton 2011).
Since the late 1990s, PAHO/WHO issue certifica-
tions of “interruption of T. cruzi transmission” by non-
native, accidentally introduced vectors. This approach 
was based on evidence that such vectors, and particu-
larly Triatoma infestans and Rhodnius prolixus, were 
strictly domestic and did not occupy natural ecotopes in 
their non-native ranges. Therefore, it was argued, those 
introduced populations could be eliminated through 
insecticide-spraying campaigns. Empirical data show 
that this idea was basically right. T. cruzi transmission 
by domestic T. infestans populations was virtually or ef-
fectively interrupted in Uruguay (certified in 1997 and 
2012), Chile (in 1999), Brazil (2006), eastern Paraguay 
(2008), some parts of Argentina (2001, 2004, 2011, 2012) 
and southern Peru and transmission by domestic R. pro-
lixus populations in southern Mexico (2009), Guatemala 
(2008), Honduras (2010), Nicaragua (2010), El Salvador 
(2010) and Costa Rica (2011) (Table I) (PAHO 2011, 
2012, Hashimoto & Schofield 2012).
Certification was intended to recognise the huge ef-
forts made by Governments and international agencies 
to achieve the specific goal of interrupting transmission 
by these non-native vectors. Native vector populations, 
which occur in natural ecotopes across their geographic 
ranges, pose a radically different problem; here we argue 
that certification of interruption of transmission has no 
role to play in this case and question who is likely to 
benefit from such a certification policy.
We first wish to note that, on purely logical grounds, 
certifying the absence of an event is absurd - the absence 
of evidence cannot be taken as evidence of absence. In 
addition, native triatomines are nearly ubiquitous in the 
Americas; many species are very efficient vectors of T. 
cruzi and some are also capable on invading and colonis-
ing artificial environments (Lent & Wygodzinsky 1979). 
Among these species are, of course, also T. infestans 
and R. prolixus, one native to the Chaco and the western 
Bolivian Andes and the other to the vast Orinoco plains 
(Table I). We also know, on empirical grounds, that spo-
radic vector-borne transmission does take place from the 
United States of America to Argentina, even in areas un-
der tight surveillance - and we know that, unfortunately, 
most surveillance systems are far too weak to confidently 
rely on the data they produce (Abad-Franch et al. 2011).
What, then, would a “certification of interruption of 
transmission by native vectors” mean? Perhaps reflect-
ing on a few recent examples (PAHO 2012) could help 
outline an answer. For what does it mean that T. cruzi 
transmission has been interrupted in, say, the Bolivian 
Department of La Paz or some localities of the Chaco 
in Argentina - where native T. infestans populations are 
common, surveillance is weak and most rural houses are 
still substandard? And what would it mean that transmis-
sion by native vectors no longer takes place in non-Ama-
zonian Brazil - where over 50 triatomine species occur, a 
dozen of which are routinely collected inside houses?
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Certifying the absence of Chagas disease transmission by native vectors lacks scientific grounds and weakens 
long-term control-surveillance systems to the detriment of people living under risk conditions. Instead, a regular 
“certification of good practice” (including vector control-surveillance, case detection/patient care and blood safety) 
could help achieve sustained disease control.
Key words: Chagas disease - vector control - interruption of transmission - certification
Interrupting Chagas disease transmission • Fernando Abad-Franch et al.252
TABLE I
Current major scenarios and general strategies in relation to Chagas disease vector control-surveillance in Latin America
Scenario Vectors Countries Strategy
Areas where transmission by 
introduced domestic vectors has 
been interrupted
Rhodnius prolixus
Triatoma infestans
Triatoma dimidiata
S Mexicoa, Guatemalaa, Hondurasa,  
El Salvadora, Nicaraguaa, Costa Ricaa
Uruguaya, Chilea, Brazila, parts of 
Argentinaa, E Paraguaya
NW Peru
Stringent surveillance 
to detect and eliminate 
infestation foci, whether 
residual or resulting from 
re-introduction
Areas where transmission by 
introduced domestic vectors has 
not yet been interrupted
R. prolixus
T. infestans
T. dimidiata
NW Colombia
S Peru
W Ecuador
Area-wide surveillance 
and control
Areas where major domestic 
vectors are native
R. prolixus
T. infestans
T. dimidiata s.l.
Colombia, N Venezuela
Bolivia, W Paraguay,
N Argentina, central-N Chile
Colombia, N Venezuela,
Mexico, all Central American
countries
Area-wide surveil-
lance with focal control, 
particularly in rural and 
periurban settings
Areas where other important 
domestic vectors are native
Mainly T. dimidiata s.l.,  
Triatoma pallidipennis, 
Triatoma barberi,  
Rhodnius ecuadoriensis, 
Triatoma carrioni,  
Triatoma maculata, 
Panstrongylus megistus, 
Triatoma brasiliensis s.l., 
Triatoma pseudomaculata
Mexico, all Central American
countries, Colombia, Venezuela,
Brazil, Ecuador, Peru, Bolivia,
Paraguay, Argentina, Chile
Area-wide surveil-
lance with focal control, 
particularly in rural and 
periurban settings
Areas with potentially  
important domestic vectors
Several phyllosoma group 
species, Triatoma venosa, 
Panstrongylus chinai, 
Panstrongylus howardi, 
Panstrongylus herreri, 
Rhodnius stali, Triatoma 
sordida, Panstrongylus 
rufotuberculatus,  
Panstrongylus lutzi,  
Rhodnius neglectus,  
Rhodnius nasutus, Triatoma 
rubrovaria, among others
Mexico, all Central American
countries, Colombia, Venezuela,
Brazil, Ecuador, Peru, Bolivia,
Uruguay, Paraguay, Argentina,
Chile
Area-wide surveil-
lance with focal control, 
particularly in rural and 
periurban settings
Areas where continuous  
transmission by non- 
domiciliated vectors has  
been documented  
(including oral transmission)
Mainly Rhodnius  
pallescens, Rhodnius  
robustus s.l., Rhodnius 
pictipes, Rhodnius brethesi, 
Panstrongylus geniculatus
Panama and probably NW Colombia, 
Orinoco and Amazon basins
Surveillance, operational 
research
Areas where sporadic  
transmission by non- 
domiciliated vectors has  
been documented  
(including oral transmission)
Many species From the United States of America to 
central-S Argentina and Chile
Surveillance, operational 
research
a: certified countries (or parts thereof) [note that the Bolivian Department of La Paz and the southern Peruvian Departments of 
Tacna and Moquegua have also been certified and that several further certification assessments are underway (PAHO 2012)].We 
stress that these strategies must always be accompanied by (i) serological screening of all blood and organ donors, (ii) integral 
patient care (diagnosis, specific chemotherapy and palliative treatment, follow-up and general support) at the primary health care 
level, with emphasis on reproductive-age women and with an adequately designed referral system for more severe cases and (iii) 
operational research (e.g., environmental management, physical protection of houses and food-processing premises, improved 
vector-detection systems or monitoring of insecticide resistance).
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One hardly controversial fact is that all available en-
tomological data are extremely fragmentary and become 
even more so as funds decline. Furthermore, we must 
remember that acute Chagas disease is “typically” asymp- 
tomatic or oligosymptomatic (Rassi et al. 2010) and goes 
often undiagnosed, and that vector detection methods 
all have very low sensitivity (Abad-Franch et al. 2011). 
Will the absence of detection be interpreted as true ab-
sence of events? (and would a single new case result in 
“de-certification”?). Note also that even the best possible 
serological survey of children born in the “post-control 
era” would not be truly informative about the occurrence 
of “sporadic” transmission. The last large survey was 
conducted in Brazil about seven years ago and it seems 
unlikely that many of similar size (and costs) will be con-
ducted in the future, because no political priority can be 
attached to a disease whose transmission by its main do-
mestic vectors has been (officially) “interrupted”. Would 
a decision-maker devote funds to monitoring the possible 
existence of events that have been declared inexistent 
by the most authoritative international health agency? 
Again, we think this highly unlikely; on the contrary, 
“certification” has usually had conspicuous “fund-freez-
ing”, priority-lessening effects. This, of course, weakens 
surveillance and a weaker surveillance system produces 
fewer records regardless of epidemiological reality, rein-
forcing the impression that transmission does not occur. 
Such a positive feed-back loop generates a false feeling 
of safety, with transmission remaining overlooked until 
the pre-control situation is restored - and control invest-
ment wasted for good. This has been quite rightly called 
“the punishment of success” (Schofield et al. 2006), a 
phenomenon whose grave effects are, unfortunately, well 
documented (Gürtler et al. 2007).
Should then PAHO/WHO stop certifying altogether? 
We do not think so: publicly acknowledging the efforts 
and achievements of health authorities is both fair and 
important. But we need to ask and answer the question 
we chose for our title: cui bono - who benefits from certi-
fication? As it currently stands, certification effectively 
discourages sustained action rather than promoting it 
and this surely does not benefit people living under risk 
conditions: they deserve better. Perhaps the simplest 
strategy would be to certify “good practice” instead of 
unverifiable facts about the non-occurrence of transmis-
sion. This would have several advantages. First, “good 
practice” is a dynamic concept - it does not focus on 
a “state” to be reached, but on better ways of running 
long-term programs, encouraging decision-makers to 
improve performance and secure adequate funds. Sec-
ond, “good practice” can be assessed periodically based 
on quantitative indicators (Table II); in defining these 
indicators, issues of validity, reliability, comparability 
and ease of ascertainment must be taken into account 
(Murray 2007). Third and perhaps most important, 
“good practice” can be defined as encompassing the 
several key aspects of Chagas disease control, includ-
ing not only vector control-surveillance, but also case 
detection/patient care and blood safety - it might even 
include a technical assessment of financial management. 
Thus, “good practice” evaluations can generate a more 
comprehensive picture of how control programs are 
performing, providing the means to dynamically detect 
and correct malfunctions. In the long run, “good prac-
TABLE II
Sustained Chagas disease vector control and surveillance: key points for functioning and assessment
What must be done
Every basic administrative unit in charge of vector-borne disease control-surveillance must have a written plan of activities 
related to Chagas disease. Such plans must:
follow national/regional technical guidelines;
establish clear goals and timelines;
have adequate funds;
provide technicians with the continuous training, equipment and materials needed to (i) carry out fieldwork, (ii) apply 
insecticides, (iii) identify vectors and parasites in the laboratory and (iv) regularly fill data forms and submit them to 
regional/national registries.
Every secondary administrative unit (from state/province/department to country) must have a supervision team capable of pro-
viding technical support to regional/local teams (including the production and distribution of guidelines) and periodically col-
lecting, managing and synthesizing the data those teams produce.
What should, in addition, be done
Chagas disease control-surveillance plans should incorporate community participation in vector detection and reporting; a strong 
component of health education, information and communication is required to stimulate participation.
Local plans should be adapted to the ecological and social reality; regional/national technical guidelines should be flexible 
enough to allow for such adaptation.
Operational research should become a routine tool to improve surveillance; local, regional and/or national health authorities should 
actively seek support from academic researchers to design projects aimed at answering practical, high-priority questions.
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tice” certification could be crucial to the strengthening 
of control programs and the prevention of new Chagas 
disease cases. It would thus directly benefit those at risk, 
whereas certifying interruption of transmission, we sus-
pect, primarily benefits authorities.
In conclusion, we strongly advocate the idea that 
PAHO/WHO, the relevant public health officials and 
the scientific community should engage in a serious de-
bate to define better ways to monitor the performance 
of Chagas disease control programs. Certifying inter-
ruption of transmission has many conceptual drawbacks 
and effectively weakens long-term control-surveillance 
systems; in contrast, periodically assessing “good prac-
tice” would stimulate sustained action and could there-
fore represent a major step in the right direction. It may 
well be, in fact, the best way forward.
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